Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3815 results
Critical Outcome Technologies, UT MD Anderson sign letter of ontent for Phase 1 development of COTI-2
Critical Outcome Technologies, the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a letter of intent ("LOI") with The University of Texas MD Anderson Cancer Center in Houston ("MD Anderson"), for the Phase 1 clinical development of the Company's lead cancer drug candidate, COTI-2, in gynecological cancers.
Drug Research > Drug Discovery & Development > News
PharmAthene, Nanotherapeutics to advance biodefense programs
PharmAthene and Nanotherapeutics, a privately-held biopharmaceutical company, have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market.
Drug Research > Drug Discovery & Development > News
Cleave starts Phase I trial of CB-5083 for multiple myeloma treatment
By PBR Staff Writer
Cleave Biosciences has started an open-label, dose escalation/dose expansion Phase I clinical trial of its lead drug candidate, CB-5083, for the treatment of patients with relapsed and refactory multiple myeloma.
Drug Research > Drug Discovery & Development > News
Sunshine Biopharma negotiates with CRO's to begin master drug file for Adva-27a anticancer compound
Sunshine Biopharma, a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has announced that it is currently negotiating with several Contract Research Organizations (CRO's) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the company's flagship anticancer compound.
Drug Research > Drug Discovery & Development > News
CMC Biologics, Zymeworks partner for bi-specific antibody product candidate
By PBR Staff Writer
CMC Biologics and Zymeworks, a Canadian biotherapeutics firm, have entered into a master services agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody.
Drug Research > Drug Discovery & Development > News
Chimerix and BARDA continu partnership in development of Brincidofovir for smallpox
Chimerix, a biopharmaceutical company developing novel, oral antivirals, has announced an award of $17m through the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of its broad spectrum antiviral brincidofovir (BCV, CMX001) as a medical countermeasure to treat smallpox.
Drug Research > Drug Discovery & Development > News
Japan develops 30-minute test to detect Ebola virus disease
By PBR Staff Writer
Researchers from the Nagasaki University in Japan, in collaboration with Eiken Chemical have developed a new method to detect the presence of the Ebola virus in just 30 minutes.
Drug Research > Drug Discovery & Development > News
Boston Scientific reports primary endpoint results of NECTAR-HF trial
By PBR Staff Writer
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation (VNS) to treat heart failure patients.
Drug Research > Drug Discovery & Development > News
Sanofi and Regeneron report positive results from four pivotal alirocumab trials
Sanofi and Regeneron Pharmaceuticals have announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.
Drug Research > Drug Discovery & Development > News
NIAID funds BioCryst's non-human primate trial of BCX4430 to treat Ebola disease
By PBR Staff Writer
BioCryst Pharmaceuticals has received an additional funding of $2.4m from the National Institute of Allergy and Infectious Diseases (NIAID) to conduct a study of an intramuscular formulation of BCX4430 in non-human primates to treat Ebola virus disease.
Drug Research > Drug Discovery & Development > News
Amgen reports positive top-line results from Phase III trial of evolocumab combination
Amgen has reported positive results from the Phase III YUKAWA-2 trial of evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol.
Drug Research > Drug Discovery & Development > News
Amerigen, Menovo partner to develop generic pharmaceuticals for US market
By PBR Staff Writer
US-based Amerigen Pharmaceuticals has entered into a collaboration agreement with Chinese firm Ningbo Menovo Pharmaceutical (Menovo) to develop generic pharmaceuticals, primarily targeting the US market.
Drug Research > Drug Discovery & Development > News
Sorrento secures NIH Grant to advance immunotherapy for IPF treatment
By PBR Staff Writer
US-based clinical oncology firm Sorrento Therapeutics has received a Small Business Innovation Research (SBIR) Phase I grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) to treat Idiopathic Pulmonary Fibrosis (IPF).
Drug Research > Drug Discovery & Development > News
Baxter reports positive top-line results from Phase III trial of BAX 855
Nektar Therapeutics reports Baxter International has announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
Drug Research > Drug Discovery & Development > News
Aldea Pharmaceuticals closes $24m series B financing
Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, has announced that it has closed a $24 million Series B equity financing.
Drug Research > Drug Discovery & Development > News
61-75 of 3815 results